
The ad, set to run during the second quarter of Super Bowl LVII on Feb. 12, features musician, actor and philanthropist Nick Jonas. Jonas lives with type 1 diabetes and uses Dexcom’s continuous glucose monitors (CGMs).
Dexcom received FDA clearance for the next-generation G7 in December 2022. The company said at the time that it planned for a launch in “early 2023. COO Jake Leach told Drug Delivery Business News shortly after clearance that the company intended to initiate a full launch without any limited efforts.
CEO Kevin Sayer later told DDBN that the company wouldn’t be taking the launch lightly.
“That launch is not going to be bashful,” Sayer said. “We’re going to be aggressive about it.”
Get the full story at our sister site, Drug Delivery Business News.